文献速递中枢神经肿瘤放疗放疗物理与技术

18F-氟环丁烷羧酸PET诊断放疗后脑转移复发的图像判读标准与诊断效能:PURSUE研究

18F-Fluciclovine for Detection of Recurrent Brain Metastases After Radiation Therapy: Image Interpretation Criteria and Diagnostic Performance From the PURSUE Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-26

PURSUE研究纳入23例放疗后MRI可疑复发脑转移患者,术前行18F-氟环丁烷羧酸PET,以病理为金标准评估定性、半定量及动态指标。结果显示SUVmax阈值为4.8时AUC达0.87,视觉判读「摄取高于腮腺」特异性高,SUVR阈值1.1可提供70%-80%敏感性和85%特异性,据此建立判读标准。

要点

  • SUVmax阈值4.8诊断复发的AUC为0.87,敏感性80%、特异性85%。
  • 视觉判读「摄取高于腮腺」特异性92%-100%,敏感性40%-80%。
  • SUVR阈值1.1提供70%-80%敏感性和85%特异性。

核心结论

  • PURSUE研究建立了经组织病理学验证的18F-氟环丁烷羧酸PET判读标准,用于诊断放疗后脑转移复发。

研究设计与样本

  • 前瞻性研究纳入23例有既往放疗后MRI可疑病灶并计划开颅的患者,行18F-氟环丁烷羧酸PET(185 MBq),以病理为金标准。
  • 由3名盲法阅片者评估静态PET图像定性阈值、半定量SUV及动态摄取指标,并由独立委员会制定判读标准。

主要发现

  • 23个参考病灶中10个(43%)经病理确认复发。
  • 注射后10-20分钟,定性指标中「摄取高于腮腺」表现最佳,特异性92%-100%、敏感性40%-80%。
  • SUVmax的ROC曲线下面积为0.87,阈值4.8时敏感性80%、特异性85%。
  • 动态指标未提供额外诊断价值。
  • 补充判读显示视觉-only判读在15-25分钟最佳,敏感性60%-90%、特异性77%-100%;SUVR阈值1.1的敏感性70%-80%、特异性85%。

关键数值与推荐

  • SUVmax阈值4.8:AUC 0.87,敏感性80%,特异性85%。
  • 视觉判读「摄取高于腮腺」:特异性92%-100%,敏感性40%-80%。
  • SUVR阈值1.1:敏感性70%-80%,特异性85%。

临床怎么用

  • 对于放疗后MRI可疑复发的脑转移病灶,可采用18F-氟环丁烷羧酸PET辅助鉴别复发与治疗相关改变。
  • 判读时可参考SUVmax阈值4.8或SUVR阈值1.1,并结合视觉判读「摄取高于腮腺」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Differentiating recurrent brain metastases (BM) from treatment-related changes after radiation therapy remains challenging. PURSUE (NCT04410367) evaluated various lesion uptake metrics to establish image interpretation criteria to detect recurrent BM with 18F-fluciclovine positron emission tomography (PET). METHODS AND MATERIALS: Patients with BM were enrolled if they had a previously irradiated MRI-equivocal "reference" lesion and were planned for craniotomy. PET with 18F-fluciclovine (185 MBq) was performed <42 days post-MRI and 1-21 days precraniotomy. Performance of different qualitative thresholds of lesion 18F-fluciclovine uptake on static PET images (10-20 minutes postinjection) versus histopathological standard of truth was assessed by 3 blinded readers, as were semiquantitative (standardized uptake value [SUV]) and dynamic uptake measures, to establish 18F-fluciclovine interpretation criteria. A separate committee reviewed all data to establish interpretation criteria. Following initial review, additional blinded reads were conducted at three timepoints (10-20, 15-25, and 20-30 minutes) to explore visual-only reads (uptake ≥ parotid/pituitary as reference) and SUV ratio (SUVR)-based criteria (SUVpeak(lesion-to-pituitary)). RESULTS: Twenty-three reference lesions from 23 subjects underwent histopathological analysis; 10 (43%) were confirmed as recurrence. At 10-20 minutes postinjection, the highest performing qualitative measure was "uptake higher than parotid" (specificity: 92%-100%; sensitivity: 40%-80% across readers). SUVmax was a high-performing metric on receiver operating characteristic analysis (area under the curve: 0.87, sensitivity: 80%, specificity: 85% for SUVmax threshold = 4.8). Dynamic measures provided no further diagnostic value. Additional reads showed visual-only interpretation was optimal at 15 to 25 minutes (sensitivity: 60%-90%; specificity: 77%-100%). SUVR-based interpretation using a threshold of 1.1 provided 70% to 80% sensitivity and 85% specificity. CONCLUSIONS: PURSUE established effective, histopathologically verified 18F-fluciclovine interpretation criteria for diagnosing recurrent BM after radiation therapy that will help evaluate 18F-fluciclovine PET in future studies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kotecha R, Chiang V, Tom MC, et al. 18F-Fluciclovine for Detection of Recurrent Brain Metastases After Radiation Therapy: Image Interpretation Criteria and Diagnostic Performance From the PURSUE Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 41759680. doi:10.1016/j.ijrobp.2026.02.239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。